EGFR mutations as a predictive marker of cytotoxic chemotherapy

Lung Cancer, 04/26/2012

The current data indicate that lung cancer patients with Epidermal growth factor receptor (EGFR)–mutations had longer progression–free survival with taxane than gemcitabine when receiving a platinum–based doublet regimen. The predictive meaning of EGFR mutations for cytotoxic chemotherapy should be further investigated.

Print Article Summary Cat 2 CME Report